Navigation Links
Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies
Date:3/9/2010

MADISON, Wis., March 9 /PRNewswire/ -- Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.  

Eight patients with advanced solid malignancies were enrolled in the trial which was designed to measure drug safety and the normal organ and whole body dosimetry of (131)I-CLR1404. Dosimetry measurements allow investigators to understand how the radiopharmaceutical will impact non-tumor organs and how it clears from the body over time. Results will be used to set the starting dose for the second Phase I study – a dose escalation study to determine the Maximum Tolerated Dose (MTD) of (131)I-CLR1404 in patients with advanced solid malignancies.

Lead investigator Joanne Mortimer, MD, Vice Chair of Medical Oncology & Therapeutics Research, City of Hope, said, "This drug candidate has the potential to treat many tumor types, including some of the most challenging. The results of this initial study will provide a better understanding of the full potential of (131)I-CLR1404 and, enable us to move forward toward determining an appropriate therapeutic dose for patients."

Cellectar's President and CEO, Bill Clarke, M.D., commented, "The dosimetry and biodistribution results of this study reveal both the initial safety profile of this drug and an approximate possible dose range that a patient could receive in a therapeutic situation. We look forward to continuing the development of (131)I-CLR1404 in order to determine the safe dose, and then to begin our efficacy studies. Having the opportunity to assess the potential of (131)I-CLR1404 therapy for solid tumor patients who have few treatment options is our primary goal."

About (131)I-CLR1404

Cellectar's (131)I-CLR1404 is a small-molecule, phospholipid ether analog that combines lipid-like properties with a cancer therapeutic beta-emitting radioisotope. Cellectar believes that this compound will benefit individuals with cancer due to its selective retention and accumulation in malignant cells versus nonmalignant cells. Preclinical animal studies demonstrated that (131)I-CLR1404 significantly slowed the growth of malignant solid tumors and resulted in improved survival.

About Cellectar

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells.  Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The company's operations are based in Madison, WI. For further information, please visit Cellectar's website at www.cellectar.com.

SOURCE Cellectar, Inc.

Back to top

RELATED LINKS
http://www.cellectar.com

'/>"/>

SOURCE Cellectar, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellectar Expands Clinical Management Team
2. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
3. Bacterin International Completes $3 Million Private Placement
4. Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
5. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
6. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
7. Valtech Cardio Ltd. Completes $17.8 Million in Series B Financing
8. SPO Medical Completes Restructuring Plan
9. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
10. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
11. Watson Completes Acquisition of Eden Biodesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):